[{"id":"essa-pharma","kind":"company","name":"ESSA Pharma","route":"/companies/essa-pharma/","commit":"1fcb3c8eab","date":"2026-09-10","author":"Jude Gomila","message":"Sources: official-website links on the remaining institutions and thirty more companies","file":"src/data/spikes/prostate.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"Official website\", url: \"https://essapharma.com\" }]"}]},{"id":"essa-pharma","kind":"company","name":"ESSA Pharma","route":"/companies/essa-pharma/","commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/sponsor-aliases.ts","type":"added","fields":[{"field":"id"},{"field":"label"},{"field":"kind"}]},{"id":"essa-pharma","kind":"company","name":"ESSA Pharma","route":"/companies/essa-pharma/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/prostate.ts","type":"changed","fields":[{"field":"tldr","before":"\"Developer of masofaniten, an AR N-terminal-domain inhibitor whose phase 2 was stopped for futility in 2024-25.\"","after":"\"ESSA Pharma developed masofaniten, an AR N-terminal-domain inhibitor whose phase 2 was stopped for futility in 2024-25.\""}]}]